_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Its a major breakthrough for women’s ovarian cancer care in Europe
The decision is based on the phase 3 DESTINY-Breast11 trial
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Subscribe To Our Newsletter & Stay Updated
